A map of metabolic phenotypes in patients with myalgic encephalomyelitis/chronic fatigue syndrome
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating disease usually presenting after infection. Emerging evidence supports that energy metabolism is affected in ME/CFS, but a unifying metabolic phenotype has not been firmly established. We performed global metabolomics, lip...
Principais autores: | Fredrik Hoel, August Hoel, Ina K.N. Pettersen, Ingrid G. Rekeland, Kristin Risa, Kine Alme, Kari Sørland, Alexander Fosså, Katarina Lien, Ingrid Herder, Hanne L. Thürmer, Merete E. Gotaas, Christoph Schäfer, Rolf K. Berge, Kristian Sommerfelt, Hans-Peter Marti, Olav Dahl, Olav Mella, Øystein Fluge, Karl J. Tronstad |
---|---|
Formato: | Artigo |
Idioma: | English |
Publicado em: |
American Society for Clinical investigation
2021-08-01
|
coleção: | JCI Insight |
Assuntos: | |
Acesso em linha: | https://doi.org/10.1172/jci.insight.149217 |
Registros relacionados
-
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients.
por: Ingrid G Rekeland, et al.
Publicado em: (2022-01-01) -
Activity monitoring and patient-reported outcome measures in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients
por: Ingrid G. Rekeland, et al.
Publicado em: (2022-01-01) -
Six-year follow-up of participants in two clinical trials of rituximab or cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
por: Ingrid G Rekeland, et al.
Publicado em: (2024-01-01) -
Reduced Endothelial Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome–Results From Open-Label Cyclophosphamide Intervention Study
por: Kari Sørland, et al.
Publicado em: (2021-03-01) -
B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment.
por: Øystein Fluge, et al.
Publicado em: (2015-01-01)